In addition to enhancing the efficacy of anti-PD-1 therapy, IAP inhibitors can also be combined with anti-cytotoxic T-lymphocyte antigen 4 to induce tumor cell sensitivity to killing. This evidence concerns the gene CD47 and neoplasm.